Editorial standards.

PeptideRadar exists to answer one question: what does the peer-reviewed literature actually say about a peptide? Our editorial standards are built around this mission, and we hold ourselves accountable to them on every page we publish.

Sources, in priority order

1. Peer-reviewed, indexed literature (PubMed, DOI-linked). Our starting point for every mechanism claim and clinical outcome.
2. Regulatory documents — FDA drug labels, EMA public assessments, USP and EP monographs, WADA prohibited lists.
3. Vendor-published certificates of analysis (COAs), cross-checked against pharmacopoeia standards where possible.
4. Community signal (Reddit, Discord, research-community forums) — reported as community signal, not as evidence.

What we do not do

• We do not make health claims. We do not say a peptide "cures" or "treats" any condition. We say what the published literature shows, and we specify the population and endpoint.
• We do not prescribe dosing. We may reference doses used in published trials, but we do not recommend doses for human use. All content is research-use-only.
• We do not publish sponsored content. No pay-for-review, no "gift bag" coverage, no undisclosed commercial arrangements.
• We do not rewrite AI-generated content and publish it as research. Our flagship pillars are written from primary sources.

Review process

Every published article carries a dated reviewer sign-off at the end. The PeptideRadar Research Desk reviews for: (1) accuracy of mechanism claims vs cited primary sources; (2) currency of regulatory statements; (3) adherence to RUO language throughout; (4) internal-link integrity.

Corrections

When we get something wrong, we say so. Corrections appear as a dated note appended to the article. We do not silently edit content when a factual error has been identified. Report errors to corrections@peptideradar.net.

AI, disclosed

We use AI tools to draft copy, to cross-reference citations, and to help surface relevant literature. All flagship research content is reviewed and rewritten from primary sources by a human editor before publication. Articles that have not been through this process are marked or removed.

Archive / rebuild note (2026-04)

As of April 2026, PeptideRadar's library is being rebuilt. Earlier auto-generated articles that did not meet this editorial standard have been set to noindex pending rewrite or removal. Our five flagship research pages (BPC-157, Tesamorelin, TB-500, Ipamorelin, Semaglutide) are the current editorial baseline.